Clinical Pilot Trial on the Effect of a Probiotic Fermented Drink on Antibiotic-associated Diarrhea (AAD)
Primary Purpose
Antibiotic-associated Diarrhea
Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
probiotic dairy drink
acidified milk
Sponsored by
About this trial
This is an interventional prevention trial for Antibiotic-associated Diarrhea focused on measuring Probiotics, Antibiotics, AAD, Helicobacter p.
Eligibility Criteria
Inclusion Criteria:
- Individuals, both genders, aged ≥ 18 y
- Helicobacter p. infected individuals, to which eradication therapy has been recommended by gastroenterologists
- Willingness to undergo the Helicobacter p. eradication therapy
- Willingness to abstain from food and supplements containing probiotics, prebiotics and fermented products except the study product
- Written informed consent
Exclusion Criteria:
- Subjects currently enrolled in another interventional trial
- subjects having finished another interventional trial within the last 4 weeks before inclusion
- incapacity to comply with the study protocol
- allergy or hypersensitivity to any component of the test product (allergy against milk protein)
- allergy or hypersensitivity to any component of the eradication therapy (e.g. penicillin allergy)
- acute GIT infections
- chronic inflammatory bowel diseases (IBD)
- irritable bowel syndrome (IBS)
- any episode of diarrhea according to WHO criteria during the last 4 weeks before inclusion
- history of lactose intolerance
- severe chronic disease (cancer, malabsorption, malnutrition, severe chronic inflammatory diseases (except chronic gastritis), renal, hepatic or cardiac diseases, artificial cardiac valve, COPD, respiratory insufficiency)
- history of active or persistent hepatitis B and C
- known congenital, acquired or iatrogenic immunodeficiency (e.g. HIV, chemotherapy, immunosuppression)
- systemic treatment with antibiotics during the last 4 weeks before inclusion
- systemic treatment likely influencing absorption, metabolism and excretion of food ingredients (metoclopramide, laxatives, body weight management and/or medication etc.)
- systemic treatment likely interfering or influencing effectiveness of the eradication drugs used e.g. ergotamine, statins, clopidogrel
- regular medical treatment including OTC, which may have impact on the study aims (e.g. probiotics, antibiotic drugs, laxatives etc.)
- severe neurological, cognitive or psychiatric diseases
- surgery or intervention requiring general anaesthesia within 2 months before the study
- vegan
- eating disorders (e.g. anorexia, bulimia)
- present alcohol and drug abuse
- pregnancy or lactation
- legal incapacity
blood parameters:
- Hb < 12 g/dL
- liver transaminases (ALT, AST) > 2-fold increased
- serum creatinine out of the normal range
- subjects who are scheduled to undergo hospitalization during the study period
Sites / Locations
- CRC Clinical Research Center Kiel
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Verum
Placebo
Arm Description
2 bottles (á 65ml) of a probiotic dairy drink consumed daily for 6 weeks
2 bottles (á 65ml) of a dairy drink containing chemically acidified milk without bacterial strains consumed daily for 6 weeks
Outcomes
Primary Outcome Measures
Occurrence of antibiotic-associated diarrhea (AAD)
Occurrence of antibiotic-associated diarrhea (AAD) (as defined by number of subjects with diarrhea within the intervention period of 6 weeks after starting antibiotic treatment; diarrhea is defined according WHO
Secondary Outcome Measures
Cumulated duration of antibiotic-associated diarrhea (AAD)
Number of days with diarrhea within the intervention period
Gastrointestinal Symptom Rating Scale
Standardized questionnaire according Dimenäs et al.
Cumulative sverity of antibiotic-associated diarrhea (AAD)
Sum of the values (obtained by transformation of Bristol stool form types) of all stools during days with diarrhea (transformation of Bristol scale types is defined: type 1 to 4 = 0; type 5 = 1; type 6 = 2 and type 7 = 3)
Full Information
NCT ID
NCT02746198
First Posted
April 12, 2016
Last Updated
February 5, 2021
Sponsor
Clinical Research Center Kiel GmbH
Collaborators
Yakult Honsha Co., LTD
1. Study Identification
Unique Protocol Identification Number
NCT02746198
Brief Title
Clinical Pilot Trial on the Effect of a Probiotic Fermented Drink on Antibiotic-associated Diarrhea (AAD)
Official Title
A Randomized Double-blind Placebo-controlled Clinical Pilot Trial on the Effect of a Probiotic Fermented Drink on Antibiotic-associated Diarrhea (AAD) in Patients With Helicobacter Pylori Eradication Therapy
Study Type
Interventional
2. Study Status
Record Verification Date
February 2021
Overall Recruitment Status
Completed
Study Start Date
January 22, 2016 (Actual)
Primary Completion Date
December 23, 2016 (Actual)
Study Completion Date
April 26, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Clinical Research Center Kiel GmbH
Collaborators
Yakult Honsha Co., LTD
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of the study is to estimate the effect of a probiotic dairy drink on occurrence and duration of AAD and gastrointestinal symptoms during Helicobacter pylori (Hp) eradication therapy and during 4 weeks thereafter and calculating the sample size for a confirmatory study.
Detailed Description
Helicobacter p. positive subjects aged ≥18 years with an indication for Helicobacter pylori (Hp) eradication recommended by a gastroenterologist should be included in the study. Subjects should be willing to consume 2 servings of the study product per day for 6 weeks, and to undergo an Hp eradication therapy for 14 days starting with the consumption period.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Antibiotic-associated Diarrhea
Keywords
Probiotics, Antibiotics, AAD, Helicobacter p.
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
125 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Verum
Arm Type
Experimental
Arm Description
2 bottles (á 65ml) of a probiotic dairy drink consumed daily for 6 weeks
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
2 bottles (á 65ml) of a dairy drink containing chemically acidified milk without bacterial strains consumed daily for 6 weeks
Intervention Type
Other
Intervention Name(s)
probiotic dairy drink
Other Intervention Name(s)
verum
Intervention Type
Other
Intervention Name(s)
acidified milk
Other Intervention Name(s)
placebo
Primary Outcome Measure Information:
Title
Occurrence of antibiotic-associated diarrhea (AAD)
Description
Occurrence of antibiotic-associated diarrhea (AAD) (as defined by number of subjects with diarrhea within the intervention period of 6 weeks after starting antibiotic treatment; diarrhea is defined according WHO
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Cumulated duration of antibiotic-associated diarrhea (AAD)
Description
Number of days with diarrhea within the intervention period
Time Frame
6 weeks
Title
Gastrointestinal Symptom Rating Scale
Description
Standardized questionnaire according Dimenäs et al.
Time Frame
6 weeks
Title
Cumulative sverity of antibiotic-associated diarrhea (AAD)
Description
Sum of the values (obtained by transformation of Bristol stool form types) of all stools during days with diarrhea (transformation of Bristol scale types is defined: type 1 to 4 = 0; type 5 = 1; type 6 = 2 and type 7 = 3)
Time Frame
6 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Individuals, both genders, aged ≥ 18 y
Helicobacter p. infected individuals, to which eradication therapy has been recommended by gastroenterologists
Willingness to undergo the Helicobacter p. eradication therapy
Willingness to abstain from food and supplements containing probiotics, prebiotics and fermented products except the study product
Written informed consent
Exclusion Criteria:
Subjects currently enrolled in another interventional trial
subjects having finished another interventional trial within the last 4 weeks before inclusion
incapacity to comply with the study protocol
allergy or hypersensitivity to any component of the test product (allergy against milk protein)
allergy or hypersensitivity to any component of the eradication therapy (e.g. penicillin allergy)
acute GIT infections
chronic inflammatory bowel diseases (IBD)
irritable bowel syndrome (IBS)
any episode of diarrhea according to WHO criteria during the last 4 weeks before inclusion
history of lactose intolerance
severe chronic disease (cancer, malabsorption, malnutrition, severe chronic inflammatory diseases (except chronic gastritis), renal, hepatic or cardiac diseases, artificial cardiac valve, COPD, respiratory insufficiency)
history of active or persistent hepatitis B and C
known congenital, acquired or iatrogenic immunodeficiency (e.g. HIV, chemotherapy, immunosuppression)
systemic treatment with antibiotics during the last 4 weeks before inclusion
systemic treatment likely influencing absorption, metabolism and excretion of food ingredients (metoclopramide, laxatives, body weight management and/or medication etc.)
systemic treatment likely interfering or influencing effectiveness of the eradication drugs used e.g. ergotamine, statins, clopidogrel
regular medical treatment including OTC, which may have impact on the study aims (e.g. probiotics, antibiotic drugs, laxatives etc.)
severe neurological, cognitive or psychiatric diseases
surgery or intervention requiring general anaesthesia within 2 months before the study
vegan
eating disorders (e.g. anorexia, bulimia)
present alcohol and drug abuse
pregnancy or lactation
legal incapacity
blood parameters:
Hb < 12 g/dL
liver transaminases (ALT, AST) > 2-fold increased
serum creatinine out of the normal range
subjects who are scheduled to undergo hospitalization during the study period
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chiyuki Kajita
Organizational Affiliation
Yakult Europe BV
Official's Role
Study Chair
Facility Information:
Facility Name
CRC Clinical Research Center Kiel
City
Kiel
State/Province
Schleswig-Holstein
ZIP/Postal Code
24118
Country
Germany
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Clinical Pilot Trial on the Effect of a Probiotic Fermented Drink on Antibiotic-associated Diarrhea (AAD)
We'll reach out to this number within 24 hrs